The role of C1GALT1C1 in lipopolysaccharide-induced IgA1 aberrant O-glycosylation in IgA nephropathy

Clinical and Investigative Medicine

Volumn 33, Issue 1, 2010, Pages

  Xie, Lin Shen ^a   Qin, Wei ^a   Fan, Jun Ming ^a,b   Huang, Jun ^a   Xie, Xi Sheng ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; C1GALT1C1 PROTEIN, HUMAN; CHAPERONE; IMMUNOGLOBULIN A; LIPOPOLYSACCHARIDE; MESSENGER RNA;

ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; CELL CULTURE; FEMALE; GENETICS; GLYCOSYLATION; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOLOGY; LYMPHOCYTE; MALE; METABOLISM; TIME; UPREGULATION;

ADOLESCENT; ADULT; AZACITIDINE; CASE-CONTROL STUDIES; CELLS, CULTURED; FEMALE; GLOMERULONEPHRITIS, IGA; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN A; LIPOPOLYSACCHARIDES; LYMPHOCYTES; MALE; MOLECULAR CHAPERONES; RNA, MESSENGER; TIME FACTORS; UP-REGULATION; YOUNG ADULT;

EID: 77249144793     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol. 2005;16:2088-97.
2. Giannakakis K, Feriozzi S, Perez M, Faraggiana T, Muda AO. Aberrantly glycosylated IgA1 in glomerular immune deposits of IgA nephropathy. J Am Soc Neph- rol. 2007;18:3139-46.
3. Narita I, Gejyo F. Pathogenetic significance of aberrant glycosylation of IgA1 in IgA nephropathy. Clin Exp Nephrol. 2008;12:332-8.
4. Allen AC, Topham PS, Harper SJ, Feehally J. Leucocyte beta 1,3 galactosyltransferase activity in IgA nephropathy. Nephrol Dial Transplant. 1997;12:701-6.
5. Qin W, Zhou Q, Yang LC, et al. Peripheral B lymphocyte beta1,3-galactosyltransferase and chaperone expression in immunoglobulin A nephropathy. J Intern Med. 2005;258:467-77.
6. Suzuki H, Moldoveanu Z, Hall S, et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest. 2008;118:629-39.
7. Smith AC, Molyneux K, Feehally J, Barratt J. O- glycosylation of serum IgA1 antibodies against muco- sal and systemic antigens in IgA nephropathy. J Am Soc Nephrol. 2006;17:3520-8.
8. Shimosawa M, Sakamoto K, Tomari Y, et al. Lipopolysaccharide-Triggered Acute Aggravation of Mesangioproliferative Glomerulonephritis through Activation of Coagulation in a High IgA Strain of ddY Mice. Nephron Exp Nephrol. 2009;112:e81-e91.
9. Endo Y, Kanbayashi H, Hara M. Experimental immu- noglobulin A nephropathy induced by gram-negative bacteria. Nephron. 1993;65:196-205.
10. Qin W, Zhong X, Fan JM, Zhang YJ, Liu XR, Ma XY. External suppression causes the low expression of the Cosmc gene in IgA nephropathy. Nephrol Dial Transplant. 2008;23:1608-14.
11. Tatemichi M, Hata H, Tazawa H, Nakadate T. Lipo- polysaccharide induces aberrant hypermethylation of Hic-1 in mouse embryonic fibroblasts lacking p53 gene. Anticancer Res. 2008;28:2101-8.
12. Felner KM, Dinter A, Cartron JP, Berger EG. Repressed beta -1,3-galactosyltransferase in the Tn syndrome. Biochim Biophys Acta. 1998;1406:115-25.
13. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.
14. Thurnher M, Rusconi S, Berger EG. Persistent repression of a functional allele can be responsible for galac-tosyltransferase deficiency in Tn syndrome. J Clin Invest. 1993;91:2103-10.
15. Weber M, Schubeler D. Genomic patterns of DNA methylation: targets and function of an epigenetic mark. Curr Opin Cell Biol. 2007;19:273-80.
16. Hashimoto S, Morohoshi K, Suzuki T, Matsushima K. Lipopolysaccharide- inducible gene expression profile in human monocytes. Scand J Infect Dis. 2003;35:619-27.
17. Tao Q, Robertson KD. Stealth technology: how Epstein-Barr virus utilizes DNA methylation to cloak itself from immune detection. Clin Immunol. 2003;109:53-63.
18. Robertson KD. DNA methylation and human disease. Nat Rev Genet. 2005;6:597-610.
19. Kaminskas E, Farrell AT, Wang YC, et al: FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist. 2005; 10:176-82.
20. Oki Y, Issa JP. Review: recent clinical trials in epige- netic therapy. Rev Recent Clin Trials. 2006; 1:169-82.
21. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA. 2002;99:3740-5.
22. Smith AC, Molyneux K, Feehally J, et al: O- glycosylation of serum IgA1 antibodies against muco- sal and systemic antigens in IgA nephropathy. J Am Soc Nephrol. 2006; 17:3520-8.
23. Layward L, Finnemore AM, Allen AC, et al: Systemic and mucosal IgA responses to systemic antigen challenge in IgA nephropathy. Clin Immunol Immunopa- thol. 1993; 69:306-13.